RGLS NASDAQ
Regulus Therapeutics Inc.
1W: -0.6%
1M: +3.2%
3M: +532.6%
1Y: +298.1%
3Y: +191.4%
5Y: -2.9%
$8.16
Last traded 2025-06-26 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$347K
+98.4% ▲
Operating Income
-$50M
-60.9% ▼
Net Income
-$46M
-54.3% ▼
EPS (Diluted)
$-0.82
+48.1% ▲
EBITDA
-$46M
-48.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $10M | $0 | $0 | $0 | $0 |
| YoY Growth | +46.5% | -100.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $15K | $459K | $122K | $21M | $347K |
| Gross Profit | $10M | -$459K | -$122K | -$21M | -$347K |
| Gross Margin | 99.8% | — | — | — | — |
| R&D Expenses | $15M | $18M | $18M | $21M | $35M |
| SG&A Expenses | $9M | $10M | $10M | $10M | $15M |
| Operating Expenses | $24M | $27M | $28M | $10M | $50M |
| Operating Income | -$14M | -$28M | -$28M | -$31M | -$50M |
| Operating Margin | -141.5% | — | — | — | — |
| Interest Expense | $2M | $855K | $688K | $604K | $158K |
| Income Before Tax | -$16M | -$28M | -$28M | -$30M | -$46M |
| Tax Expense | $0 | $1K | $1K | $1K | $1K |
| Net Income | -$16M | -$28M | -$28M | -$30M | -$46M |
| Net Margin | -157.2% | — | — | — | — |
| EPS (Diluted) | $-4.50 | $-3.24 | $-1.86 | $-1.58 | $-0.82 |
| EBITDA | -$13M | -$27M | -$28M | -$31M | -$46M |
| Shares Outstanding | 3M | 9M | 15M | 19M | 56M |